Andreas H. Groll mainly investigates Intensive care medicine, Aspergillosis, Micafungin, Internal medicine and Amphotericin B. The study incorporates disciplines such as Guideline, Clinical trial, Neutropenia and Antifungal in addition to Intensive care medicine. His Aspergillosis research includes elements of Voriconazole and Aspergillus.
His studies in Micafungin integrate themes in fields like Echinocandin and Pharmacology. The Internal medicine study combines topics in areas such as Caspofungin and Posaconazole. Andreas H. Groll has included themes like Surgery and Galactomannan in his Amphotericin B study.
His primary areas of study are Internal medicine, Intensive care medicine, Pharmacology, Pharmacokinetics and Transplantation. His research in Internal medicine intersects with topics in Gastroenterology, Surgery and Caspofungin. His Intensive care medicine study integrates concerns from other disciplines, such as Clinical trial, Epidemiology, Antifungal, Voriconazole and Aspergillosis.
Itraconazole is closely connected to Fluconazole in his research, which is encompassed under the umbrella topic of Voriconazole. His biological study spans a wide range of topics, including Aspergillus fumigatus and Aspergillus. His Pharmacology research is multidisciplinary, incorporating perspectives in Amphotericin B and Toxicity.
His scientific interests lie mostly in Internal medicine, Intensive care medicine, Hematopoietic stem cell transplantation, Transplantation and Epidemiology. His Intensive care medicine study combines topics from a wide range of disciplines, such as Clinical trial, Guideline and Itraconazole, Voriconazole, Posaconazole. His Posaconazole research integrates issues from Gastroenterology, Amphotericin B deoxycholate, Fluconazole, Mucormycosis and Pharmacology.
His Transplantation research is multidisciplinary, incorporating perspectives in Bone marrow failure, Opportunistic infection, Echinocandin and Acute leukemia. His studies in Epidemiology integrate themes in fields like Toxoplasmosis, Disease, Disease burden, Chronic infection and Aspergillosis. His research investigates the connection with Pharmacokinetics and areas like Amphotericin B which intersect with concerns in Chemoprophylaxis.
Andreas H. Groll focuses on Internal medicine, Intensive care medicine, Clinical trial, Guideline and Disease. Andreas H. Groll has included themes like Invasive fungal disease, Amphotericin B and Pharmacodynamics in his Intensive care medicine study. His Amphotericin B study incorporates themes from Chemoprophylaxis, Echinocandin and Dosing.
He usually deals with Clinical trial and limits it to topics linked to Pharmacokinetics and Tolerability. His research investigates the link between Guideline and topics such as Disease management that cross with problems in Aspergillosis, Rare disease and Mucormycosis. His work in Aspergillosis is not limited to one particular discipline; it also encompasses Epidemiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
O.A. Cornely;M. Bassetti;T. Calandra;J. Garbino.
Clinical Microbiology and Infection (2012)
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.
A.H. Groll;P.M. Shah;C. Mentzel;M. Schneider.
Journal of Infection (1996)
Infections due to emerging and uncommon medically important fungal pathogens.
T.J. Walsh;A. Groll;J. Hiemenz;R. Fleming.
Clinical Microbiology and Infection (2004)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning.
Clinical Microbiology and Infection (2018)
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
O.A. Cornely;S. Arikan-Akdagli;E. Dannaoui;A.H. Groll.
Clinical Microbiology and Infection (2014)
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007
A. Skiada;L. Pagano;A. Groll;S. Zimmerli.
Clinical Microbiology and Infection (2011)
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
Thomas J. Walsh;Irja Lutsar;Timothy Driscoll;Bertrand Dupont.
Pediatric Infectious Disease Journal (2002)
Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development
Andreas H. Groll;Stephen C. Piscitelli;Thomas J. Walsh.
Advances in pharmacology (San Diego) (1998)
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly;Sharon C. Chen;Carol A. Kauffman;William J. Steinbach.
Clinical Infectious Diseases (2020)
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
Helen W. Boucher;Andreas H. Groll;Christine C. Chiou;Thomas J. Walsh.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: